UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma

Scientific reports, 2022-04, Vol.12 (1), p.6286-6286, Article 6286

2022

Volltextzugriff (PDF)

FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?

Molecular imaging and biology, 2022, Vol.24 (5), p.807-817

2022

Volltextzugriff (PDF)

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma

European journal of nuclear medicine and molecular imaging, 2021-06, Vol.48 (6), p.1902-1914

2021

Volltextzugriff (PDF)

Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003

PloS one, 2020, Vol.15 (3), p.e0230526-e0230526

2020

Volltextzugriff (PDF)

Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro

PloS one, 2022, Vol.17 (4), p.e0267543-e0267543

2022

Volltextzugriff (PDF)

The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest

Leukemia, 2020-05, Vol.34 (5), p.1315-1328

2020

Volltextzugriff (PDF)

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

PloS one, 2015-06, Vol.10 (6), p.e0128816-e0128816

2015

Volltextzugriff (PDF)

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines

Frontiers in oncology, 2019-11, Vol.9, p.1301-1301

2019

Volltextzugriff (PDF)

Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice

Current radiopharmaceuticals, 2013-06, Vol.6 (2), p.106-116

2013

Volltextzugriff (PDF)

Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab

PloS one, 2012, Vol.7 (8), p.e42345

2012

Volltextzugriff (PDF)

177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice

PloS one, 2014, Vol.9 (7), p.e103070

2014

Volltextzugriff (PDF)

Bystander effects in UV-induced genomic instability: antioxidants inhibit delayed mutagenesis induced by ultraviolet A and B radiation

Journal of carcinogenesis, 2005-08, Vol.4 (1), p.11-11

2005

Volltextzugriff (PDF)

In Vitro Cytotoxicity of Low-Dose-Rate Radioimmunotherapy by the Alpha-Emitting Radioimmunoconjugate Thorium-227–DOTA–Rituximab

International journal of radiation oncology, biology, physics, 2009-11, Vol.75 (3), p.886-895

2009

Volltextzugriff (PDF)

The role of serotonin and p53 status in the radiation-induced bystander effect

International journal of radiation biology, 2012-10, Vol.88 (10), p.773-776

2012

Volltextzugriff (PDF)

Genome-wide microarray analysis of human fibroblasts in response to γ radiation and the radiation-induced bystander effect

Radiation research, 2012-01, Vol.177 (1), p.35

2012

Volltextzugriff (PDF)

Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates

Current radiopharmaceuticals, 2011-10, Vol.4 (4), p.321-328

2011

Volltextzugriff (PDF)

Targeted alpha therapy with 212Pb-NNV003 for the treatment of CD37 positive B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)

The Journal of nuclear medicine (1978), 2019-05, Vol.60

2019

Volltextzugriff (PDF)

Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Blood, 2018-11, Vol.132 (Supplement 1), p.4422-4422

2018

Volltextzugriff (PDF)

Transcriptional responses in irradiated and bystander fibroblasts after low dose α-particle radiation

International journal of radiation biology, 2012-10, Vol.88 (10), p.713-719

2012

Volltextzugriff (PDF)

Targeted Alpha-Particle Therapy with 227Th-Labeled Antibodies

Current radiopharmaceuticals, 2008-09, Vol.1 (3), p.209-214

2008

Volltextzugriff (PDF)

B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-Life

Blood, 2022-11, Vol.140 (Supplement 1), p.6012-6013

2022

Volltextzugriff (PDF)

NNV024, a Humanized Anti-CD37 Antibody with Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell Malignancies

Blood, 2022-11, Vol.140 (Supplement 1), p.3123-3124

2022

Volltextzugriff (PDF)

Myelosuppression in patients treated with 177 Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable

Acta oncologica, 2021-11, Vol.60 (11), p.1481-1488

2021

Volltextzugriff (PDF)

Anti-CD37 radioimmunotherapy with .sup.177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro

PloS one, 2022-04, Vol.17 (4), p.e0267543

2022

Volltextzugriff (PDF)

Combination of 177Lu-lilotomab satetraxetan with rituximab synergistically improves in-vivo therapeutic efficacy in a rituximab-resistant non-Hodgkin lymphoma (NHL) model

The Journal of nuclear medicine (1978), 2019-05, Vol.60

2019

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(128)

Sprache

Englisch
(127)
Norwegisch
(3)

Erscheinungsjahr

n.n

Thema

Animals
(36)
Humans
(33)
Science & Technology
(32)
Life Sciences & Biomedicine
(29)
Mice
(27)
Lymphoma
(22)
Radioimmunotherapy
(22)
Female
(18)
Rituximab
(16)
Tumors
(16)
Oncology
(15)
Cell Line, Tumor
(14)
Radiology, Nuclear Medicine & Medical Imaging
(14)
Toxicity
(14)
Monoclonal Antibodies
(13)
Tissue Distribution
(13)
Cell Line
(12)
Immunotherapy
(11)
Lutetium Isotopes
(11)
Mice, Nude
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma

FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma

Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003

Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro

The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines

Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice

Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab

177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice

Bystander effects in UV-induced genomic instability: antioxidants inhibit delayed mutagenesis induced by ultraviolet A and B radiation

In Vitro Cytotoxicity of Low-Dose-Rate Radioimmunotherapy by the Alpha-Emitting Radioimmunoconjugate Thorium-227–DOTA–Rituximab

The role of serotonin and p53 status in the radiation-induced bystander effect

Genome-wide microarray analysis of human fibroblasts in response to γ radiation and the radiation-induced bystander effect

Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates

Targeted alpha therapy with 212Pb-NNV003 for the treatment of CD37 positive B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)

Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Transcriptional responses in irradiated and bystander fibroblasts after low dose α-particle radiation

Targeted Alpha-Particle Therapy with 227Th-Labeled Antibodies

B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-Life

NNV024, a Humanized Anti-CD37 Antibody with Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell Malignancies

Myelosuppression in patients treated with 177 Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable

Anti-CD37 radioimmunotherapy with .sup.177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro

Combination of 177Lu-lilotomab satetraxetan with rituximab synergistically improves in-vivo therapeutic efficacy in a rituximab-resistant non-Hodgkin lymphoma (NHL) model

Suchergebnisse filtern